Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) have been assigned a consensus recommendation of “Hold” from the eleven analysts that are covering the firm, MarketBeat reports. Eight analysts have rated the stock with a hold recommendation, two have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $4.79.

Several brokerages have recently weighed in on MRNS. JMP Securities reiterated a “market perform” rating on shares of Marinus Pharmaceuticals in a report on Thursday, October 24th. Royal Bank of Canada lowered their target price on Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating for the company in a report on Friday, October 25th. Oppenheimer upgraded Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price target on the stock in a research note on Monday, September 23rd. TD Cowen restated a “hold” rating on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. Finally, HC Wainwright reiterated a “neutral” rating and set a $2.00 target price on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th.

Hedge Funds Weigh In On Marinus Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in MRNS. Point72 DIFC Ltd bought a new stake in shares of Marinus Pharmaceuticals in the 2nd quarter valued at about $28,000. AQR Capital Management LLC boosted its stake in Marinus Pharmaceuticals by 70.3% in the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 12,934 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Marinus Pharmaceuticals in the second quarter valued at approximately $64,000. World Investment Advisors LLC acquired a new position in shares of Marinus Pharmaceuticals during the third quarter worth $104,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Marinus Pharmaceuticals during the second quarter worth $206,000. 98.80% of the stock is currently owned by institutional investors.

Marinus Pharmaceuticals Stock Down 0.4 %

MRNS stock opened at $0.54 on Wednesday. The firm’s fifty day simple moving average is $0.36 and its two-hundred day simple moving average is $1.00. The stock has a market capitalization of $29.76 million, a price-to-earnings ratio of -0.22 and a beta of 1.03. Marinus Pharmaceuticals has a twelve month low of $0.22 and a twelve month high of $10.50.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.